Article
Oncology
Martin Glas, Matthew T. Ballo, Ze'ev Bomzon, Noa Urman, Shay Levi, Gitit Lavy-Shahaf, Suriya Jeyapalan, Terence T. Sio, Paul M. DeRose, Martin Misch, Sophie Taillibert, Zvi Ram, Andreas F. Hottinger, Jacob Easaw, Chae-Yong Kim, Suyash Mohan, Roger Stupp
Summary: TTFields treatment affects the rate of distant progression in newly diagnosed GBM patients, with distant lesions appearing further from the primary lesion in the TTFields treatment arm. Distant progression correlates with improved clinical outcomes in TTFields patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Biochemistry & Molecular Biology
Qiong Wu, Anders E. Berglund, Robert J. Macaulay, Arnold B. Etame
Summary: This study provides evidence that the epigenetic reactivation of Tumor Suppressor Candidate 3 (TUSC3) can reprogram the sensitivity of glioblastoma stem cells (GSCs) to Temozolomide (TMZ), regardless of the promoter methylation status of the DNA repair gene O6-methylguanine DNA methyltransferase (MGMT). These findings offer a framework for further exploring TUSC3-mediated epigenetic reprogramming strategies to enhance TMZ sensitivity and outcomes in glioblastoma multiforme (GBM).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Sebastian Brandner, Alexandra McAleenan, Claire Kelly, Francesca Spiga, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Claire L. Faulkner, Christopher Wragg, Sarah Jefferies, Julian P. T. Higgins, Kathreena M. Kurian
Summary: In this study, different techniques for measuring MGMT in glioblastoma patients treated with temozolomide were compared, with Methylation-specific PCR (MSP) and pyrosequencing (PSQ) found to be more prognostic than immunohistochemistry. The study did not provide strong evidence on the optimal use of frozen tissue vs formalin-fixed paraffin-embedded tissues or the best CpG sites or threshold. Therefore, further research is needed to determine the most effective methods for predicting survival in these patients.
Article
Oncology
Mario Caccese, Matteo Simonelli, Veronica Villani, Simona Rizzato, Tamara Ius, Francesco Pasqualetti, Marco Russo, Roberta Ruda, Rosina Amoroso, Luisa Bellu, Roberta Bertorelle, Francesco Cavallin, Angelo Dipasquale, Mariantonia Carosi, Stefano Pizzolitto, Daniela Cesselli, Pasquale Persico, Beatrice Casini, Matteo Fassan, Vittorina Zagonel, Giuseppe Lombardi
Summary: The study investigated the association between MGMT promoter methylation status and overall survival in glioblastoma patients, finding better survival when MGMT > 15% but a more complex, non-linear relationship between MGMT methylation and survival.
Article
Biochemistry & Molecular Biology
Konstantin R. Brawanski, Susanne Sprung, Christian F. Freyschlag, Romana Hoeftberger, Thomas Stroebel, Johannes Haybaeck, Claudius Thome, Claudia Manzl, Anna M. Birkl-Toeglhofer
Summary: This study investigated the associations between MGMT promoter methylation, MGMT and MMR protein expression, and their effect on overall survival (OS) and progression-free survival (PFS) in patients with glioblastoma. The results showed that MGMT promoter methylation is associated with improved OS in glioblastoma patients younger than 70 years old, while the extent of surgery has a larger impact on overall survival in elderly patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Michael Lim, Michael Weller, Ahmed Idbaih, Joachim Steinbach, Gaetano Finocchiaro, Raju R. Raval, George Ansstas, Joachim Baehring, Jennie W. Taylor, Jerome Honnorat, Kevin Petrecca, Filip De Vos, Antje Wick, Ashley Sumrall, Solmaz Sahebjam, Ingo K. Mellinghoff, Masashi Kinoshita, Mustimbo Roberts, Ruta Slepetis, Deepti Warad, David Leung, Michelle Lee, David A. Reardon, Antonio Omuro
Summary: The study evaluated the addition of the immune checkpoint inhibitor nivolumab (NIVO) to radiotherapy (RT) + temozolomide (TMZ) in newly diagnosed glioblastoma patients and found that it did not improve survival in these patients.
Article
Oncology
Maher Kurdi, Nadeem Shafique Butt, Saleh Baeesa, Badrah Alghamdi, Yazid Maghrabi, Anas Bardeesi, Rothaina Saeedi, Taghreed Al-Sinani, Najla Alghanmi, Mohammed O. Bari, Alaa Samkari, Ahmed Lary
Summary: This study investigated the relationship between IDH1 mutation and MGMT promoter methylation with recurrence-free interval in glioblastoma patients. The findings showed that both IDH1 mutation and MGMT methylation are independent prognostic factors in glioblastoma.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Article
Neurosciences
Matthew McCord, Pouya Jamshidi, Vineeth Thirunavu, Lucas Santana-Santos, Erica Vormittag-Nocito, David Dittman, Stephanie Parker, Joseph Baczkowski, Lawrence Jennings, Jordain Walshon, Kathleen McCortney, Kristyn Galbraith, Hui Zhang, Rimas V. Lukas, Roger Stupp, Karan Dixit, Priya Kumthekar, Amy B. Heimberger, Matija Snuderl, Craig Horbinski
Summary: This study aimed to determine whether driver mutation variant allelic frequency (VAF) could serve as an objective metric for cellularity in MGMT promoter methylation testing and identify possible false-negative samples. The results showed that microscopic examination tended to overestimate tumor cellularity when VAF was low, and re-testing low-VAF cases using methylation array and droplet digital PCR (ddPCR) confirmed the presence of false-negative cases.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2023)
Article
Oncology
Vasileios K. Kavouridis, Keith L. Ligon, Patrick Y. Wen, J. Bryan Iorgulescu
Summary: In a national analysis, temozolomide was associated with prolonged overall survival in gliosarcoma patients. These results provide support for the current practice of trimodal therapy for gliosarcoma.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Medicine, General & Internal
Anja Smits, Malgorzata Lysiak, Andreas Magnusson, Johan Rosell, Peter Soderkvist, Annika Malmstrom
Summary: In IDHwt glioblastoma, there is a higher proportion of MGMT promoter methylation in female patients, leading to a better treatment response. Therefore, patient sex and MGMT promoter methylation are key determinants that should be considered before making treatment decisions.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Duyen Thi Do, Ming-Ren Yang, Luu Ho Thanh Lam, Nguyen Quoc Khanh Le, Yu-Wei Wu
Summary: Using a radiomics-based machine learning model, we can predict the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in glioblastoma multiforme (GBM) patients preoperatively and noninvasively. The model achieved high accuracy and specificity using a genetic algorithm-based feature selection method, indicating potential wide application in both low- and high-grade gliomas.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Maria del Mar Alvarez-Torres, Elies Fuster-Garcia, Carmen Balana, Josep Puig, Juan M. Garcia-Gomez
Summary: Despite comprehensive treatment with surgery, chemotherapy, and radiotherapy, glioblastoma patients still face a poor prognosis. Extending adjuvant chemotherapy may benefit patients with moderate vascularity and methylated MGMT, but does not show benefits for highly vascular tumors, even in the presence of MGMT methylation.
Article
Oncology
Isabella Gomes, Daniel Antunes Moreno, Mariana Bisarro dos Reis, Luciane Sussuchi da Silva, Leticia Ferro Leal, Gisele Melo Goncalves, Caio Augusto Pereira, Marco Antonio Oliveira, Marcus de Medeiros Matsushita, Rui Manuel Reis
Summary: The study found that MGMTp methylation was closely associated with TMZ treatment response, MGMT expression was negatively correlated with MGMTp methylation, and low MGMT expression was significantly associated with better patient survival.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Cell Biology
Cyntanna C. Hawkins, Amber B. Jones, Emily R. Gordon, Yuvika Harsh, Julia K. Ziebro, Christopher D. Willey, Corinne Griguer, David K. Crossman, Sara J. Cooper, Sasanka Ramanadham, Ninh Doan, Anita B. Hjelmeland
Summary: Sphingolipid metabolism is dysregulated in GBM, leading to cell evasion of apoptosis. This study found that the mRNA levels of acid ceramidase, a key enzyme in S1P production, were elevated in recurrent GBM. Inhibiting acid ceramidase decreased cell growth and increased apoptosis in TMZ-resistant GBM cells, suggesting the potential utility of targeting sphingolipid metabolism in recurrent GBM.
CELL DEATH DISCOVERY
(2023)
Article
Oncology
Jan-Michael Werner, Johannes Weller, Garry Ceccon, Christina Schaub, Caroline Tscherpel, Philipp Lohmann, Elena K. Bauer, Niklas Schaefer, Gabriele Stoffels, Christian Baues, Eren Celik, Simone Marnitz, Christoph Kabbasch, Gerrit H. Gielen, Gereon R. Fink, Karl-Josef Langen, Ulrich Herrlinger, Norbert Galldiks
Summary: The study evaluated the value of FET-PET parameters in diagnosing pseudoprogression related to lomustine-temozolomide chemoradiation, finding that TBRmean had the highest accuracy in identifying pseudoprogression. Furthermore, integrating relative changes of TBRmean improved accuracy, and combining static and dynamic parameters increased specificity to 100%.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Thomas R. Reich, Olivier J. Switzeny, Mirjam Renovanz, Clemens Sommer, Bernd Kaina, Markus Christmann, Maja T. Tomicic
Article
Biochemistry & Molecular Biology
Dorthe Aasland, Thomas R. Reich, Maja T. Tomicic, Olivier J. Switzeny, Bernd Kaina, Markus Christmann
JOURNAL OF NEUROCHEMISTRY
(2018)
Article
Cell Biology
Katja Zappe, Angelika Pointner, Olivier J. Switzeny, Ulrich Magnet, Elena Tomeva, Jutta Heller, George Mare, Karl-Heinz Wagner, Siegfried Knasmueller, Alexander G. Haslberger
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2018)
Article
Multidisciplinary Sciences
Jutta Zwielehner, Cornelia Lassl, Berit Hippe, Angelika Pointner, Olivier J. Switzeny, Marlene Remely, Elvira Kitzweger, Reinhard Ruckser, Alexander G. Haslberger
Article
Multidisciplinary Sciences
Antje Motzek, Jelena Knezevic, Olivier J. Switzeny, Alexis Cooper, Ivo Baric, Robert Beluzic, Kevin A. Strauss, Erik G. Puffenberger, S. Harvey Mudd, Oliver Vugrek, Ulrich Zechner
Article
Oncology
Wynand P. Roos, Steve Quiros, Andrea Krumm, Stephanie Merz, Olivier Jerome Switzeny, Markus Christmann, Carmen Loquai, Bernd Kaina
Article
Oncology
Olivier J. Switzeny, Elisabeth Muellner, Karl-Heinz Wagner, Helmut Brath, Eva Aumueller, Alexander G. Haslberger
CLINICAL EPIGENETICS
(2012)
Article
Cell Biology
Stephanie Lilja, Julia Oldenburg, Angelika Pointner, Laura Dewald, Mariam Lerch, Berit Hippe, Olivier Switzeny, Alexander Haslberger
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2020)